LumiThera announced today that it closed the second tranche of its Series C financing round with more than $10 million raised. The photobiomodulation (PBM) treatment developer earmarked the proceeds from the funding round for further clinical testing and commercialization of its Valeda light delivery system for treating dry age-related macular degeneration (AMD). LumiThera’s Valeda system […]
LumiThera said today it inked a distribution deal with Nikon (TYO:7731) subsidiary Optos to distribute its Valeda light delivery system intended for use in treating dry age-related macular degeneration. The deal will position Optos as the exclusive distributor of the device in 12 European countries, the Seattle-based company said. The device has already won CE Mark approval in the […]
Nikon (TYO:7731) subsidiary Optos and Google (NSDQ:GOOG) unit Verily inked a deal this week to develop technologies for machine learning-enabled retinal imaging. The deal calls for the companies will collaborate on improving the screening for diabetic retinopathy and diabetic macular edema, both among the leading causes of blindness worldwide. The program combines Nikon’s leadership in optical engineering and precision […]
A Hattiesburg, Miss.-based doctor says Optos‘ (LON:OPTS) Optomap retinal imaging camera helped him identify a particularly deadly blood vessel blockage before it could trigger a heart attack, according to the Hattiesburg American. During a demonstration of the system, Dr. David Richardson of Hattiesburg Eye Clinic was scanned by the mapping system which captures a panorama […]
March 2, 2015 by Brad Perriello
(Reuters) – Nikon, the 98-year-old Japanese company best known for its cameras, has agreed to buy British retinal imaging firm Optos for 259.3 million pounds ($400 million) as it moves into the medical sector.
Nikon has previously said it intended to enter the medical sector to leverage its optical technologies and the Japanese group sees buying Optos as an important step in that long-term growth plan.
Kazuo Ushida, president of Nikon, said the company would expand the medical business further in the future.
Considered a leader in diabetes research, Zisser will be involved with a variety of clinical research projects and serve as a medical liaison between Insulet and government leaders, the FDA, and healthcare organizations, Bedford, Mass.-based Insulet said.
Bottomley served in the U.K.’s House of Commons from 1984 to 2005, after which she was raised to "peerage," a term of ranking for British nobility.